Search | Clinical Trials Finder

Conditions: Encephalitis, Encephalitis, Viral, Infectious Encephalitis, Virus Diseases, Encephalomyelitis, Venezuelan Equine, Brain Diseases, Central Nervous System Diseases, Central Nervous System Viral Diseases, Alphavirus Infections, Togaviridae Infections, RNA Virus Infections, Central Nervous System Infections, Encephalomyelitis, Physiological Effects of Drugs, Vaccines, Encephalomyelitis, Equine, Nervous System Diseases
Interventions: Vaccinations on Day 0, Day 28, and Day 140; Biological
Lead sponsor: SRI International; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Plymouth, Michigan

Conditions: HIV Infections
Interventions: EnvDNA, PolyEnv1, EnvPro; Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years to 35 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hookworm Infection, Hookworm Disease
Interventions: 10 μg Na-GST-1/Alhydrogel, 30 μg Na-GST-1/Alhydrogel, 100 μg Na-GST-1/Alhydrogel, 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg), 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg), 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg), 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg); Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Chikungunya Virus
Interventions: CHIKV VLP vaccine, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Fountain Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more

Conditions: Campylobacter Infection
Interventions: Capsule-Conjugate Campylobacter Vaccine (CJCV1), Alhydrogel®, aluminum hydroxide adjuvant (alum); Biological · Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: HIV Prevention
Interventions: PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV
Interventions: CD4BS CH505M5 Pr-NP1, CH505TF chTrimer, 3M-052-AF (labeled as AP 60-702), Aluminum Hydroxide Suspension (Alum), ACU-026-001-1 (labeled as empty LNP); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Birmingham, Alabama • Atlanta, Georgia • Nashville, Tennessee

Conditions: Zika Virus Infection
Interventions: Saline, Zika Virus Purified Inactivated Vaccine (ZPIV); Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: West Nile Virus Disease
Interventions: WN-80E; Biological
Lead sponsor: Hawaii Biotech, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Influenza Prevention
Interventions: INFLUENZA G1 mHA, Placebo, Al(OH)3; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Miami Lakes, Florida • Lenexa, Kansas • Metairie, Louisiana + 1 more

Conditions: Healthy Volunteer, HIV Vaccine
Interventions: Ad4-mgag, Ad4-EnvC150, Placebo Comparator, AIDSVAX B/E; Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Rotavirus Infection
Interventions: P2-VP8 subunit rotavirus vaccine, placebo; Biological · Other
Lead sponsor: PATH; Other
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Zika Virus Infection
Interventions: IXIARO, Placebo, YF Vax 17D Strain, Zika Virus Purified Inactivated Vaccine (ZPIV); Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12, sargramostim, tyrosinase peptide, alum adjuvant, adjuvant therapy; Biological · Drug · Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: COVID-19
Interventions: Aluminum Hydroxide Suspension, Boost-2867, CpG 7909, Sodium Chloride, 0.9%; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 5 more

Conditions: Dengue
Interventions: V180, Alhydrogel™, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 3
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: Streptococcus Pneumoniae
Interventions: Placebo, GEN-004 Low Dose, GEN-004 Low Dose + Adjuvant, GEN-004 Mid Dose, GEN-004 Mid Dose + Adjuvant, GEN-004 High Dose, GEN-004 High Dose + Adjuvant; Biological
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Dengue
Interventions: TDENV-LAV, TDENV-PIV 4 µg + alum adjuvant; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Hookworm Infection
Interventions: Na-ASP-2/Alhydrogel Hookworm Vaccine, Saline placebo; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Respiratory Syncytial Virus
Interventions: VRC-RSVRGP084-00-VP, Aluminum Hydroxide Suspension; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV
Interventions: 16055 NFL delta Gly4 trimer, Trimer 4571, Ad4-Env145NFL, 5 x 108 viral particles (vp); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more

Conditions: HIV Infections
Interventions: gp145 C.6980 Vaccine, Placebo, Aluminum Hydroxide Adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant; Biological
Lead sponsor: Madhu Chhanda Choudhary; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Columbus, Ohio • Pittsburgh, Pennsylvania

Conditions: Hookworm Infection, Hookworm Disease
Interventions: Na-APR-1 (M74)/Alhydrogel®, Gluco-Pyranosylphospho-Lipid A Aqueous Formulation; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine

Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults

Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

ZIKA Vaccine in Naive Subjects

Safety Study of HBV-002 West Nile Vaccine in Healthy Adults

A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults

Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults

A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)

Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine

TDENV PIV and LAV Dengue Prime-boost Strategy

Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection

Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults

Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults